Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Nghiem, P; Bhatia, S; Lipson, EJ; Sharfman, WH; Kudchadkar, RR; Friedlander, PA; Brohl, AS; Daud, A; Kluger, HM; Reddy, SA; Burgess, MA; Hanks, BA; Olencki, T; Boulmay, BC; Lundgren, LM; Ramchurren, N; Homet Moreno, B; Sharon, E; Cheever, MA; Topalian, SL

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • 9506 - 9506

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.9506